The Evolving Therapy of Rheumatic Diseases, The Future is Now

E-ISSN： 1875-5917|2|1|1-11

ISSN： 1568-0088

Source： Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol.2, Iss.1, 2002-04, pp. : 1-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inflammatory lipids as a target for therapy in the rheumatic diseases

By McMahon Maureen Brahn Ernest

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 8, 2008-08 ,pp. : 1213-1224

Informa Healthcare

Access to resources Recommend Favorite

Synthetic Peptides: The Future of Patient Management in Systemic Rheumatic Diseases?

Current Medicinal Chemistry, Vol. 14, Iss. 26, 2007-11 ,pp. : 2831-2838

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-Interleukin-6 Receptor Antibody Therapy in Rheumatic Diseases

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 6, Iss. 4, 2006-12 ,pp. : 373-381

Bentham Science Publishers

Access to resources Recommend Favorite

Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases

By Stamp Lisa K Roberts Rebecca L

Pharmacogenomics, Vol. 12, Iss. 10, 2011-10 ,pp. : 1449-1463

Future Medicine

Access to resources Recommend Favorite

Engineering high avidity CTLA4Ig for therapy of rheumatic diseases

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 9, 2002-09 ,pp. : 1455-1457

Informa Healthcare

Access to resources Recommend Favorite